FEATURE: Obtaining reimbursement for innovative products in Europe
This article was originally published in Clinica
What are the options for manufacturers to receive reimbursement for technologies that do not yet have an appropriate code within national European reimbursement systems? That is the question addressed in this article, the second in a series by Carolyn Semple Piggot and colleagues at the UK-based Translucency network
You may also be interested in...
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.
No device-related warning letters were released by the US FDA the week of 19 February.
Complex generics and value added medicines share common challenges on harmonization of regulation, lack of incentives and clarity of guidelines, heard delegates to Medicines for Europe’s Regulatory & Scientific Affairs conference.